Cross-reactive CD8+ T cell responses to tumor-associated antigens (TAAs) and homologous microbiota-derived antigens (MoAs)
We have recently shown extensive sequence and conformational homology between tumor-associated antigens (TAAs) and antigens derived from microorganisms (MoAs). The present study aimed to assess the breadth of T-cell recognition specific to MoAs and the corresponding TAAs in healthy subjects (HS) and...
Saved in:
Published in | Journal of experimental & clinical cancer research Vol. 43; no. 1; pp. 87 - 14 |
---|---|
Main Authors | , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
England
BioMed Central Ltd
20.03.2024
BioMed Central BMC |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | We have recently shown extensive sequence and conformational homology between tumor-associated antigens (TAAs) and antigens derived from microorganisms (MoAs). The present study aimed to assess the breadth of T-cell recognition specific to MoAs and the corresponding TAAs in healthy subjects (HS) and patients with cancer (CP).
A library of > 100 peptide-MHC (pMHC) combinations was used to generate DNA-barcode labelled multimers. Homologous peptides were selected from the Cancer Antigenic Peptide Database, as well as Bacteroidetes/Firmicutes-derived peptides. They were incubated with CD8 + T cells from the peripheral blood of HLA-A*02:01 healthy individuals (n = 10) and cancer patients (n = 16). T cell recognition was identified using tetramer-staining analysis. Cytotoxicity assay was performed using as target cells TAP-deficient T2 cells loaded with MoA or the paired TuA.
A total of 66 unique pMHC recognized by CD8+ T cells across all groups were identified. Of these, 21 epitopes from microbiota were identified as novel immunological targets. Reactivity against selected TAAs was observed for both HS and CP. pMHC tetramer staining confirmed CD8+ T cell populations cross-reacting with CTA SSX2 and paired microbiota epitopes. Moreover, PBMCs activated with the MoA where shown to release IFNγ as well as to exert cytotoxic activity against cells presenting the paired TuA.
Several predicted microbiota-derived MoAs are recognized by T cells in HS and CP. Reactivity against TAAs was observed also in HS, primed by the homologous bacterial antigens. CD8+ T cells cross-reacting with MAGE-A1 and paired microbiota epitopes were identified in three subjects. Therefore, the microbiota can elicit an extensive repertoire of natural memory T cells to TAAs, possibly able to control tumor growth ("natural anti-cancer vaccination"). In addition, non-self MoAs can be included in preventive/therapeutic off-the-shelf cancer vaccines with more potent anti-tumor efficacy than those based on TAAs. |
---|---|
AbstractList | BackgroundWe have recently shown extensive sequence and conformational homology between tumor-associated antigens (TAAs) and antigens derived from microorganisms (MoAs). The present study aimed to assess the breadth of T-cell recognition specific to MoAs and the corresponding TAAs in healthy subjects (HS) and patients with cancer (CP).MethodA library of > 100 peptide-MHC (pMHC) combinations was used to generate DNA-barcode labelled multimers. Homologous peptides were selected from the Cancer Antigenic Peptide Database, as well as Bacteroidetes/Firmicutes-derived peptides. They were incubated with CD8 + T cells from the peripheral blood of HLA-A*02:01 healthy individuals (n = 10) and cancer patients (n = 16). T cell recognition was identified using tetramer-staining analysis. Cytotoxicity assay was performed using as target cells TAP-deficient T2 cells loaded with MoA or the paired TuA.ResultsA total of 66 unique pMHC recognized by CD8+ T cells across all groups were identified. Of these, 21 epitopes from microbiota were identified as novel immunological targets. Reactivity against selected TAAs was observed for both HS and CP. pMHC tetramer staining confirmed CD8+ T cell populations cross-reacting with CTA SSX2 and paired microbiota epitopes. Moreover, PBMCs activated with the MoA where shown to release IFNγ as well as to exert cytotoxic activity against cells presenting the paired TuA.ConclusionsSeveral predicted microbiota-derived MoAs are recognized by T cells in HS and CP. Reactivity against TAAs was observed also in HS, primed by the homologous bacterial antigens. CD8+ T cells cross-reacting with MAGE-A1 and paired microbiota epitopes were identified in three subjects. Therefore, the microbiota can elicit an extensive repertoire of natural memory T cells to TAAs, possibly able to control tumor growth (“natural anti-cancer vaccination”). In addition, non-self MoAs can be included in preventive/therapeutic off-the-shelf cancer vaccines with more potent anti-tumor efficacy than those based on TAAs. Background We have recently shown extensive sequence and conformational homology between tumor-associated antigens (TAAs) and antigens derived from microorganisms (MoAs). The present study aimed to assess the breadth of T-cell recognition specific to MoAs and the corresponding TAAs in healthy subjects (HS) and patients with cancer (CP). Method A library of > 100 peptide-MHC (pMHC) combinations was used to generate DNA-barcode labelled multimers. Homologous peptides were selected from the Cancer Antigenic Peptide Database, as well as Bacteroidetes/Firmicutes-derived peptides. They were incubated with CD8 + T cells from the peripheral blood of HLA-A*02:01 healthy individuals (n = 10) and cancer patients (n = 16). T cell recognition was identified using tetramer-staining analysis. Cytotoxicity assay was performed using as target cells TAP-deficient T2 cells loaded with MoA or the paired TuA. Results A total of 66 unique pMHC recognized by CD8+ T cells across all groups were identified. Of these, 21 epitopes from microbiota were identified as novel immunological targets. Reactivity against selected TAAs was observed for both HS and CP. pMHC tetramer staining confirmed CD8+ T cell populations cross-reacting with CTA SSX2 and paired microbiota epitopes. Moreover, PBMCs activated with the MoA where shown to release IFN[gamma] as well as to exert cytotoxic activity against cells presenting the paired TuA. Conclusions Several predicted microbiota-derived MoAs are recognized by T cells in HS and CP. Reactivity against TAAs was observed also in HS, primed by the homologous bacterial antigens. CD8+ T cells cross-reacting with MAGE-A1 and paired microbiota epitopes were identified in three subjects. Therefore, the microbiota can elicit an extensive repertoire of natural memory T cells to TAAs, possibly able to control tumor growth ("natural anti-cancer vaccination"). In addition, non-self MoAs can be included in preventive/therapeutic off-the-shelf cancer vaccines with more potent anti-tumor efficacy than those based on TAAs. We have recently shown extensive sequence and conformational homology between tumor-associated antigens (TAAs) and antigens derived from microorganisms (MoAs). The present study aimed to assess the breadth of T-cell recognition specific to MoAs and the corresponding TAAs in healthy subjects (HS) and patients with cancer (CP). A library of > 100 peptide-MHC (pMHC) combinations was used to generate DNA-barcode labelled multimers. Homologous peptides were selected from the Cancer Antigenic Peptide Database, as well as Bacteroidetes/Firmicutes-derived peptides. They were incubated with CD8 + T cells from the peripheral blood of HLA-A*02:01 healthy individuals (n = 10) and cancer patients (n = 16). T cell recognition was identified using tetramer-staining analysis. Cytotoxicity assay was performed using as target cells TAP-deficient T2 cells loaded with MoA or the paired TuA. A total of 66 unique pMHC recognized by CD8+ T cells across all groups were identified. Of these, 21 epitopes from microbiota were identified as novel immunological targets. Reactivity against selected TAAs was observed for both HS and CP. pMHC tetramer staining confirmed CD8+ T cell populations cross-reacting with CTA SSX2 and paired microbiota epitopes. Moreover, PBMCs activated with the MoA where shown to release IFNγ as well as to exert cytotoxic activity against cells presenting the paired TuA. Several predicted microbiota-derived MoAs are recognized by T cells in HS and CP. Reactivity against TAAs was observed also in HS, primed by the homologous bacterial antigens. CD8+ T cells cross-reacting with MAGE-A1 and paired microbiota epitopes were identified in three subjects. Therefore, the microbiota can elicit an extensive repertoire of natural memory T cells to TAAs, possibly able to control tumor growth ("natural anti-cancer vaccination"). In addition, non-self MoAs can be included in preventive/therapeutic off-the-shelf cancer vaccines with more potent anti-tumor efficacy than those based on TAAs. We have recently shown extensive sequence and conformational homology between tumor-associated antigens (TAAs) and antigens derived from microorganisms (MoAs). The present study aimed to assess the breadth of T-cell recognition specific to MoAs and the corresponding TAAs in healthy subjects (HS) and patients with cancer (CP).BACKGROUNDWe have recently shown extensive sequence and conformational homology between tumor-associated antigens (TAAs) and antigens derived from microorganisms (MoAs). The present study aimed to assess the breadth of T-cell recognition specific to MoAs and the corresponding TAAs in healthy subjects (HS) and patients with cancer (CP).A library of > 100 peptide-MHC (pMHC) combinations was used to generate DNA-barcode labelled multimers. Homologous peptides were selected from the Cancer Antigenic Peptide Database, as well as Bacteroidetes/Firmicutes-derived peptides. They were incubated with CD8 + T cells from the peripheral blood of HLA-A*02:01 healthy individuals (n = 10) and cancer patients (n = 16). T cell recognition was identified using tetramer-staining analysis. Cytotoxicity assay was performed using as target cells TAP-deficient T2 cells loaded with MoA or the paired TuA.METHODA library of > 100 peptide-MHC (pMHC) combinations was used to generate DNA-barcode labelled multimers. Homologous peptides were selected from the Cancer Antigenic Peptide Database, as well as Bacteroidetes/Firmicutes-derived peptides. They were incubated with CD8 + T cells from the peripheral blood of HLA-A*02:01 healthy individuals (n = 10) and cancer patients (n = 16). T cell recognition was identified using tetramer-staining analysis. Cytotoxicity assay was performed using as target cells TAP-deficient T2 cells loaded with MoA or the paired TuA.A total of 66 unique pMHC recognized by CD8+ T cells across all groups were identified. Of these, 21 epitopes from microbiota were identified as novel immunological targets. Reactivity against selected TAAs was observed for both HS and CP. pMHC tetramer staining confirmed CD8+ T cell populations cross-reacting with CTA SSX2 and paired microbiota epitopes. Moreover, PBMCs activated with the MoA where shown to release IFNγ as well as to exert cytotoxic activity against cells presenting the paired TuA.RESULTSA total of 66 unique pMHC recognized by CD8+ T cells across all groups were identified. Of these, 21 epitopes from microbiota were identified as novel immunological targets. Reactivity against selected TAAs was observed for both HS and CP. pMHC tetramer staining confirmed CD8+ T cell populations cross-reacting with CTA SSX2 and paired microbiota epitopes. Moreover, PBMCs activated with the MoA where shown to release IFNγ as well as to exert cytotoxic activity against cells presenting the paired TuA.Several predicted microbiota-derived MoAs are recognized by T cells in HS and CP. Reactivity against TAAs was observed also in HS, primed by the homologous bacterial antigens. CD8+ T cells cross-reacting with MAGE-A1 and paired microbiota epitopes were identified in three subjects. Therefore, the microbiota can elicit an extensive repertoire of natural memory T cells to TAAs, possibly able to control tumor growth ("natural anti-cancer vaccination"). In addition, non-self MoAs can be included in preventive/therapeutic off-the-shelf cancer vaccines with more potent anti-tumor efficacy than those based on TAAs.CONCLUSIONSSeveral predicted microbiota-derived MoAs are recognized by T cells in HS and CP. Reactivity against TAAs was observed also in HS, primed by the homologous bacterial antigens. CD8+ T cells cross-reacting with MAGE-A1 and paired microbiota epitopes were identified in three subjects. Therefore, the microbiota can elicit an extensive repertoire of natural memory T cells to TAAs, possibly able to control tumor growth ("natural anti-cancer vaccination"). In addition, non-self MoAs can be included in preventive/therapeutic off-the-shelf cancer vaccines with more potent anti-tumor efficacy than those based on TAAs. Abstract Background We have recently shown extensive sequence and conformational homology between tumor-associated antigens (TAAs) and antigens derived from microorganisms (MoAs). The present study aimed to assess the breadth of T-cell recognition specific to MoAs and the corresponding TAAs in healthy subjects (HS) and patients with cancer (CP). Method A library of > 100 peptide-MHC (pMHC) combinations was used to generate DNA-barcode labelled multimers. Homologous peptides were selected from the Cancer Antigenic Peptide Database, as well as Bacteroidetes/Firmicutes-derived peptides. They were incubated with CD8 + T cells from the peripheral blood of HLA-A*02:01 healthy individuals (n = 10) and cancer patients (n = 16). T cell recognition was identified using tetramer-staining analysis. Cytotoxicity assay was performed using as target cells TAP-deficient T2 cells loaded with MoA or the paired TuA. Results A total of 66 unique pMHC recognized by CD8+ T cells across all groups were identified. Of these, 21 epitopes from microbiota were identified as novel immunological targets. Reactivity against selected TAAs was observed for both HS and CP. pMHC tetramer staining confirmed CD8+ T cell populations cross-reacting with CTA SSX2 and paired microbiota epitopes. Moreover, PBMCs activated with the MoA where shown to release IFNγ as well as to exert cytotoxic activity against cells presenting the paired TuA. Conclusions Several predicted microbiota-derived MoAs are recognized by T cells in HS and CP. Reactivity against TAAs was observed also in HS, primed by the homologous bacterial antigens. CD8+ T cells cross-reacting with MAGE-A1 and paired microbiota epitopes were identified in three subjects. Therefore, the microbiota can elicit an extensive repertoire of natural memory T cells to TAAs, possibly able to control tumor growth (“natural anti-cancer vaccination”). In addition, non-self MoAs can be included in preventive/therapeutic off-the-shelf cancer vaccines with more potent anti-tumor efficacy than those based on TAAs. |
ArticleNumber | 87 |
Audience | Academic |
Author | Ragone, Concetta Hadrup, Sine Reker Izzo, Francesco Tvingsholm, Siri Amanda Tornesello, Maria Lina Cavalluzzo, Beatrice Tagliamonte, Maria Manolio, Carmen Mauriello, Angela Morabito, Alessandro Buonaguro, Luigi Viuff, Marie Christine Buonaguro, Franco M. |
Author_xml | – sequence: 1 givenname: Beatrice surname: Cavalluzzo fullname: Cavalluzzo, Beatrice – sequence: 2 givenname: Marie Christine surname: Viuff fullname: Viuff, Marie Christine – sequence: 3 givenname: Siri Amanda surname: Tvingsholm fullname: Tvingsholm, Siri Amanda – sequence: 4 givenname: Concetta surname: Ragone fullname: Ragone, Concetta – sequence: 5 givenname: Carmen surname: Manolio fullname: Manolio, Carmen – sequence: 6 givenname: Angela surname: Mauriello fullname: Mauriello, Angela – sequence: 7 givenname: Franco M. surname: Buonaguro fullname: Buonaguro, Franco M. – sequence: 8 givenname: Maria Lina surname: Tornesello fullname: Tornesello, Maria Lina – sequence: 9 givenname: Francesco surname: Izzo fullname: Izzo, Francesco – sequence: 10 givenname: Alessandro surname: Morabito fullname: Morabito, Alessandro – sequence: 11 givenname: Sine Reker surname: Hadrup fullname: Hadrup, Sine Reker – sequence: 12 givenname: Maria surname: Tagliamonte fullname: Tagliamonte, Maria – sequence: 13 givenname: Luigi orcidid: 0000-0002-6380-7114 surname: Buonaguro fullname: Buonaguro, Luigi |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/38509571$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kktv1DAUhSNURB_wB1igSEioCAXsPPxYVaPhVamIzbC2bpybjEdJPNhOJebX4zQtmnbBynFyzqd7T855cjLaEZPkNSUfKRXsk6cFKVlG8jIjBSFldniWnFFesUxKxk6Onk-Tc-93hDAqqXyRnBaiIrLi9Cw5rJ31PnMIOphbTNefxYd0k2rs-9Sh39vRo0-DTcM0WJeB91YbCNikMAbT4ejTy81q5d_He5Nu7WB729nJp4PRztbGBsgadBF97Phho-Nl8ryF3uOr-_Mi-fX1y2b9Pbv5-e16vbrJdJWLkGkKgtOKCKwa0tbIOICgglCQJZZ1yysEJuscmxhBzKLmTJNWShQUo6coLpLrhdtY2Km9MwO4P8qCUXcvrOsUuGB0jyovcl2TFjXWoqRAoAbR8FI3rIkoyCPramHtp3rARuMYHPSPoI-_jGarOnuraMy7oCWNhMt7grO_J_RBDcbPccOIMTeVS15QQhmdpW-fSHd2cmPMShWk4IKXlMmoereoOogbbBH6sPW2n4KJ_06tuGCy5JKTKHxzPPu_oR_KEAViEei5Ew5bpU2AmRNXMX3cQc29U0vvVMxa3fVOHaI1f2J9oP_H9BdV9Nsj |
CitedBy_id | crossref_primary_10_4103_bbrj_bbrj_271_24 crossref_primary_10_1007_s11427_024_2831_x crossref_primary_10_1177_17588359251324882 crossref_primary_10_1136_jitc_2024_010192 crossref_primary_10_3390_biomedicines12112429 |
Cites_doi | 10.1038/nprot.2012.037 10.1002/(sici)1097-0215(19980703)77:1<19::aid-ijc4>3.0.co;2-2 10.1016/s0169-5002(03)00244-7 10.3390/cancers11010038 10.1016/s0952-7915(96)80019-7 10.1016/j.cell.2009.09.033 10.1016/s0167-5699(98)01299-7 10.1126/science.aan3706 10.1186/s12967-018-1662-9 10.1084/jem.20020242 10.3389/fimmu.2021.769799 10.1097/00000658-199608000-00011 10.1186/s12967-022-03512-6 10.1084/jem.20160526 10.1016/j.csbj.2021.12.035 10.1038/nbt.3662 10.1038/ni.f.219 10.3390/microorganisms7010014 10.1073/pnas.0909122107 10.1038/ni.2640 10.1084/jem.190.5.705 10.1084/jem.184.2.647 10.1158/1078-0432.CCR-07-1909 10.3390/cancers14010140 10.1126/science.abc4552 10.1038/nature09944 10.1016/j.chom.2012.08.004 10.1016/j.ctrv.2018.04.009 10.1136/gutjnl-2019-319654 10.1038/s41579-020-0433-9 10.1016/j.ymthe.2020.12.005 10.1172/JCI32205 10.1016/j.ceb.2015.08.002 10.1016/j.mib.2013.03.009 10.1016/j.immuni.2015.01.010 10.1002/ijc.2910630313 10.1042/BCJ20160510 10.1111/imm.13037 10.1186/s12943-023-01776-0 10.1186/s12885-021-08720-9 10.1038/nmeth.1345 10.4049/jimmunol.174.3.1709 10.1186/s12967-022-03681-4 10.1038/nri.2017.7 10.1016/j.mam.2023.101192 |
ContentType | Journal Article |
Copyright | 2024. The Author(s). COPYRIGHT 2024 BioMed Central Ltd. 2024. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. The Author(s) 2024 |
Copyright_xml | – notice: 2024. The Author(s). – notice: COPYRIGHT 2024 BioMed Central Ltd. – notice: 2024. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: The Author(s) 2024 |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH K9. M0S M1P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI 7X8 5PM DOA |
DOI | 10.1186/s13046-024-03004-z |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni) Medical Database ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Open Access Full Text |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Central ProQuest Health & Medical Complete Health Research Premium Collection ProQuest Medical Library ProQuest One Academic UKI Edition Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection ProQuest Central (New) ProQuest One Academic ProQuest One Academic (New) ProQuest Medical Library (Alumni) ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | Publicly Available Content Database MEDLINE MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1756-9966 |
EndPage | 14 |
ExternalDocumentID | oai_doaj_org_article_232cb0feceb841a0aba8d74cd6d8e5a2 PMC10953141 A786947970 38509571 10_1186_s13046_024_03004_z |
Genre | Journal Article |
GeographicLocations | United States--US |
GeographicLocations_xml | – name: United States--US |
GrantInformation_xml | – fundername: Regione Campania grantid: POR FESR 2014/2020 "Campania OncoTerapie" – fundername: Ministero della Salute grantid: "Ricerca Corrente" Project L2/3 – fundername: Ministero della Salute grantid: "Ricerca Corrente" Project L2/13 |
GroupedDBID | --- 0R~ 29K 2WC 4.4 5GY 5VS 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML AAYXX ABDBF ABUWG ACGFO ACGFS ADBBV ADRAZ ADUKV AENEX AFKRA AFPKN AHBYD AHMBA AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AOIJS BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CITATION CS3 D-I DIK DU5 E3Z EBD EBLON EBS ESX F5P FYUFA GROUPED_DOAJ HMCUK HYE IAO IEA IHR IHW INH INR ITC KQ8 M1P M48 M~E O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PQQKQ PROAC PSQYO RBZ RNS ROL RPM RSV SMD SOJ TR2 TUS UKHRP ~8M -5E -5G -A0 -BR 3V. ACRMQ ADINQ C24 CGR CUY CVF ECM EIF NPM 7XB 8FK AZQEC DWQXO K9. PJZUB PKEHL PPXIY PQEST PQUKI 7X8 5PM PUEGO |
ID | FETCH-LOGICAL-c528t-c1a871508e5d0fbe67aa81801a94e4bf75ea69b2ed004024b76c0f99e81e8e533 |
IEDL.DBID | M48 |
ISSN | 1756-9966 0392-9078 |
IngestDate | Wed Aug 27 01:19:44 EDT 2025 Thu Aug 21 18:34:43 EDT 2025 Fri Jul 11 16:13:40 EDT 2025 Sat Jul 26 00:18:52 EDT 2025 Thu May 22 21:26:04 EDT 2025 Wed Feb 19 02:11:13 EST 2025 Tue Jul 01 02:26:52 EDT 2025 Thu Apr 24 22:55:38 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Language | English |
License | 2024. The Author(s). Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c528t-c1a871508e5d0fbe67aa81801a94e4bf75ea69b2ed004024b76c0f99e81e8e533 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
ORCID | 0000-0002-6380-7114 |
OpenAccessLink | https://doaj.org/article/232cb0feceb841a0aba8d74cd6d8e5a2 |
PMID | 38509571 |
PQID | 3037874169 |
PQPubID | 105475 |
PageCount | 14 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_232cb0feceb841a0aba8d74cd6d8e5a2 pubmedcentral_primary_oai_pubmedcentral_nih_gov_10953141 proquest_miscellaneous_2973101611 proquest_journals_3037874169 gale_healthsolutions_A786947970 pubmed_primary_38509571 crossref_citationtrail_10_1186_s13046_024_03004_z crossref_primary_10_1186_s13046_024_03004_z |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2024-03-20 |
PublicationDateYYYYMMDD | 2024-03-20 |
PublicationDate_xml | – month: 03 year: 2024 text: 2024-03-20 day: 20 |
PublicationDecade | 2020 |
PublicationPlace | England |
PublicationPlace_xml | – name: England – name: London |
PublicationTitle | Journal of experimental & clinical cancer research |
PublicationTitleAlternate | J Exp Clin Cancer Res |
PublicationYear | 2024 |
Publisher | BioMed Central Ltd BioMed Central BMC |
Publisher_xml | – name: BioMed Central Ltd – name: BioMed Central – name: BMC |
References | JL Round (3004_CR12) 2010; 107 TS Ghosh (3004_CR39) 2020; 69 B Cavalluzzo (3004_CR32) 2021; 14 C Ragone (3004_CR25) 2022; 20 E Rinninella (3004_CR3) 2019; 7 O Türeci (3004_CR37) 1998; 77 M Tagliamonte (3004_CR33) 2021; 12 E Schooten (3004_CR36) 2018; 67 M Otte (3004_CR43) 2001; 61 II Ivanov (3004_CR14) 2009; 139 Y Fan (3004_CR6) 2021; 19 V Dutoit (3004_CR23) 2002; 196 G Bricard (3004_CR45) 2005; 174 B Routy (3004_CR8) 2018; 359 C Zang (3004_CR44) 2021; 21 Y Shen (3004_CR13) 2012; 12 DJ Loftus (3004_CR21) 1996; 184 RS Andersen (3004_CR29) 2012; 7 JR Brestoff (3004_CR5) 2013; 14 C Manolio (3004_CR31) 2022; 20 M Tagliamonte (3004_CR34) 2023; 22 CM Paulos (3004_CR10) 2007; 117 D Mason (3004_CR19) 1998; 19 A Khosravi (3004_CR4) 2013; 16 M Arumugam (3004_CR2) 2011; 473 SR Hadrup (3004_CR28) 2009; 6 S Piquer-Esteban (3004_CR38) 2021; 20 E Thursby (3004_CR1) 2017; 474 L Buonaguro (3004_CR26) 2021; 29 MG von Herrath (3004_CR16) 1996; 8 GD Sepich-Poore (3004_CR7) 2021; 371 A Petrizzo (3004_CR30) 2018; 16 M Levy (3004_CR17) 2017; 17 F Brasseur (3004_CR41) 1995; 63 C Gur (3004_CR11) 2015; 42 JL Weon (3004_CR46) 2015; 37 N Tai (3004_CR18) 2016; 213 ML Sprouse (3004_CR15) 2019; 156 L Vujanovic (3004_CR24) 2007; 13 AK Bentzen (3004_CR27) 2016; 34 M Mori (3004_CR40) 1996; 224 MJ Pittet (3004_CR22) 1999; 190 K Tajima (3004_CR42) 2003; 42 S Vivarelli (3004_CR9) 2019; 11 KC Garcia (3004_CR20) 2009; 10 L Buonaguro (3004_CR35) 2023; 92 |
References_xml | – volume: 7 start-page: 891 issue: 5 year: 2012 ident: 3004_CR29 publication-title: Nat Protoc doi: 10.1038/nprot.2012.037 – volume: 77 start-page: 19 issue: 1 year: 1998 ident: 3004_CR37 publication-title: Int J Cancer doi: 10.1002/(sici)1097-0215(19980703)77:1<19::aid-ijc4>3.0.co;2-2 – volume: 42 start-page: 23 issue: 1 year: 2003 ident: 3004_CR42 publication-title: Lung Cancer doi: 10.1016/s0169-5002(03)00244-7 – volume: 11 start-page: 38 issue: 1 year: 2019 ident: 3004_CR9 publication-title: Cancers (Basel) doi: 10.3390/cancers11010038 – volume: 8 start-page: 878 issue: 6 year: 1996 ident: 3004_CR16 publication-title: Curr Opin Immunol doi: 10.1016/s0952-7915(96)80019-7 – volume: 139 start-page: 485 issue: 3 year: 2009 ident: 3004_CR14 publication-title: Cell doi: 10.1016/j.cell.2009.09.033 – volume: 19 start-page: 395 issue: 9 year: 1998 ident: 3004_CR19 publication-title: Immunol Today doi: 10.1016/s0167-5699(98)01299-7 – volume: 359 start-page: 91 issue: 6371 year: 2018 ident: 3004_CR8 publication-title: Science doi: 10.1126/science.aan3706 – volume: 16 start-page: 286 issue: 1 year: 2018 ident: 3004_CR30 publication-title: J Transl Med doi: 10.1186/s12967-018-1662-9 – volume: 196 start-page: 207 issue: 2 year: 2002 ident: 3004_CR23 publication-title: J Exp Med doi: 10.1084/jem.20020242 – volume: 12 start-page: 769799 year: 2021 ident: 3004_CR33 publication-title: Front Immunol doi: 10.3389/fimmu.2021.769799 – volume: 224 start-page: 183 issue: 2 year: 1996 ident: 3004_CR40 publication-title: Ann Surg doi: 10.1097/00000658-199608000-00011 – volume: 20 start-page: 316 issue: 1 year: 2022 ident: 3004_CR25 publication-title: J Transl Med doi: 10.1186/s12967-022-03512-6 – volume: 213 start-page: 2129 issue: 10 year: 2016 ident: 3004_CR18 publication-title: J Exp Med doi: 10.1084/jem.20160526 – volume: 61 start-page: 6682 issue: 18 year: 2001 ident: 3004_CR43 publication-title: Cancer Res – volume: 20 start-page: 421 year: 2021 ident: 3004_CR38 publication-title: Comput Struct Biotechnol J doi: 10.1016/j.csbj.2021.12.035 – volume: 34 start-page: 1037 issue: 10 year: 2016 ident: 3004_CR27 publication-title: Nat Biotechnol doi: 10.1038/nbt.3662 – volume: 10 start-page: 143 issue: 2 year: 2009 ident: 3004_CR20 publication-title: Nat Immunol doi: 10.1038/ni.f.219 – volume: 7 start-page: 14 issue: 1 year: 2019 ident: 3004_CR3 publication-title: Microorganisms doi: 10.3390/microorganisms7010014 – volume: 107 start-page: 12204 issue: 27 year: 2010 ident: 3004_CR12 publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.0909122107 – volume: 14 start-page: 676 issue: 7 year: 2013 ident: 3004_CR5 publication-title: Nat Immunol doi: 10.1038/ni.2640 – volume: 190 start-page: 705 issue: 5 year: 1999 ident: 3004_CR22 publication-title: J Exp Med doi: 10.1084/jem.190.5.705 – volume: 184 start-page: 647 issue: 2 year: 1996 ident: 3004_CR21 publication-title: J Exp Med doi: 10.1084/jem.184.2.647 – volume: 13 start-page: 6796 issue: 22 Pt 1 year: 2007 ident: 3004_CR24 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-07-1909 – volume: 14 start-page: 140 issue: 1 year: 2021 ident: 3004_CR32 publication-title: Cancers (Basel) doi: 10.3390/cancers14010140 – volume: 371 start-page: eabc4552 issue: 6536 year: 2021 ident: 3004_CR7 publication-title: Science doi: 10.1126/science.abc4552 – volume: 473 start-page: 174 issue: 7346 year: 2011 ident: 3004_CR2 publication-title: Nature doi: 10.1038/nature09944 – volume: 12 start-page: 509 issue: 4 year: 2012 ident: 3004_CR13 publication-title: Cell Host Microbe doi: 10.1016/j.chom.2012.08.004 – volume: 67 start-page: 54 year: 2018 ident: 3004_CR36 publication-title: Cancer Treat Rev doi: 10.1016/j.ctrv.2018.04.009 – volume: 69 start-page: 1218 issue: 7 year: 2020 ident: 3004_CR39 publication-title: Gut doi: 10.1136/gutjnl-2019-319654 – volume: 19 start-page: 55 issue: 1 year: 2021 ident: 3004_CR6 publication-title: Nat Rev Microbiol doi: 10.1038/s41579-020-0433-9 – volume: 29 start-page: 10 issue: 1 year: 2021 ident: 3004_CR26 publication-title: Mol Ther doi: 10.1016/j.ymthe.2020.12.005 – volume: 117 start-page: 2197 issue: 8 year: 2007 ident: 3004_CR10 publication-title: J Clin Invest doi: 10.1172/JCI32205 – volume: 37 start-page: 1 year: 2015 ident: 3004_CR46 publication-title: Curr Opin Cell Biol doi: 10.1016/j.ceb.2015.08.002 – volume: 16 start-page: 221 issue: 2 year: 2013 ident: 3004_CR4 publication-title: Curr Opin Microbiol doi: 10.1016/j.mib.2013.03.009 – volume: 42 start-page: 344 issue: 2 year: 2015 ident: 3004_CR11 publication-title: Immunity doi: 10.1016/j.immuni.2015.01.010 – volume: 63 start-page: 375 issue: 3 year: 1995 ident: 3004_CR41 publication-title: Int J Cancer doi: 10.1002/ijc.2910630313 – volume: 474 start-page: 1823 issue: 11 year: 2017 ident: 3004_CR1 publication-title: Biochem J doi: 10.1042/BCJ20160510 – volume: 156 start-page: 305 issue: 4 year: 2019 ident: 3004_CR15 publication-title: Immunology doi: 10.1111/imm.13037 – volume: 22 start-page: 75 issue: 1 year: 2023 ident: 3004_CR34 publication-title: Mol Cancer doi: 10.1186/s12943-023-01776-0 – volume: 21 start-page: 1007 issue: 1 year: 2021 ident: 3004_CR44 publication-title: BMC Cancer doi: 10.1186/s12885-021-08720-9 – volume: 6 start-page: 520 issue: 7 year: 2009 ident: 3004_CR28 publication-title: Nat Methods doi: 10.1038/nmeth.1345 – volume: 174 start-page: 1709 issue: 3 year: 2005 ident: 3004_CR45 publication-title: J Immunol doi: 10.4049/jimmunol.174.3.1709 – volume: 20 start-page: 472 issue: 1 year: 2022 ident: 3004_CR31 publication-title: J Transl Med doi: 10.1186/s12967-022-03681-4 – volume: 17 start-page: 219 issue: 4 year: 2017 ident: 3004_CR17 publication-title: Nat Rev Immunol doi: 10.1038/nri.2017.7 – volume: 92 start-page: 101192 year: 2023 ident: 3004_CR35 publication-title: Mol Aspects Med doi: 10.1016/j.mam.2023.101192 |
SSID | ssj0061919 |
Score | 2.401632 |
Snippet | We have recently shown extensive sequence and conformational homology between tumor-associated antigens (TAAs) and antigens derived from microorganisms (MoAs).... Background We have recently shown extensive sequence and conformational homology between tumor-associated antigens (TAAs) and antigens derived from... BackgroundWe have recently shown extensive sequence and conformational homology between tumor-associated antigens (TAAs) and antigens derived from... Abstract Background We have recently shown extensive sequence and conformational homology between tumor-associated antigens (TAAs) and antigens derived from... |
SourceID | doaj pubmedcentral proquest gale pubmed crossref |
SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
StartPage | 87 |
SubjectTerms | Analysis Antigenic determinants Antigens Antigens, Neoplasm Bar codes Binomial distribution Cancer CD8-Positive T-Lymphocytes Epitopes, T-Lymphocyte Ethylenediaminetetraacetic acid Histocompatibility antigens HLA histocompatibility antigens Humans Immune system Lymphocytes Microbiota Microbiota (Symbiotic organisms) Neoplasms Peptides Peptides - chemistry Software T cells Tumors |
SummonAdditionalLinks | – databaseName: DOAJ Open Access Full Text dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3Ni9QwFA-yB_Eirp_VVSN4UJawTT_S9DiOLoswnmZhbyFfZRecVqYdD_PX73tJp0wR9OKxTUObvK_fa5LfI-SjwQpIprFMSGNZoTPwg0aUkKp4L6XRAEkwUVz9EFfXxfeb8uao1BfuCYv0wHHiLiDiW5M23nojC65TbbR0VWGdcNKXOnhfiHmHZCr6YMgKeH04IiPFRc9xAZBBPGIpUkyx_SwMBbb-P33yUVCab5g8ikCXT8jjETrSRfzkU_LAt0_Jw9W4OP6M7Jf4KgYoMPgwuvwqz-ma4q95uo1bYX1Ph44Ou023ZXoUjHcUZhdJOXv6ab1Y9J_h2tHbboN-sdv1dHMX2ZoGzRwo7O9Zj1UHPZ6T68tv6-UVG0srMFtmcmCWa8iUAJz50qWN8aLSGk99c10XvjBNVXotapN5h1aeFaYSNm3q2kvuoU-evyAnbdf6V4SKvLGYJLnM6iIsXNa5xqzQ5RakVCeEH2Za2ZF3HMtf_FQh_5BCRekoeI0K0lH7hJxPfX5F1o2_Pv0FBTg9iYzZ4QbokRr1SP1LjxLyHsWv4vHTye7VopKiLqq6ShNydtAMNRp6rwABgMsDVAvj_DA1g4micHXrQUoqlAdDaM0T8jIq0vStuQTEVlbQImcqNhvMvKW9uw004BypAnnBX_-P4b8hj7JoHuA3z8jJsN35twC3BvMuWNY9O8AopA priority: 102 providerName: Directory of Open Access Journals – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Jb9QwFLagSIgLYidQwEgcQJXVLI7jnNAwUFVIw2kqzc3yFlqJmZRJhsP8et5zPKERUo-JY8XJ277n5XuEfDBYAck0lglpLOM6Bz9oRAmpivdSGg2QBBPFxQ9xfsG_r8pVnHDr4rbKg08Mjtq1FufIT8HVgm4BfKg_X_9mWDUKV1djCY275B5Sl-GWrmo1JlyQG4TCHhAhBUNcfzg0I8Vpl-GSIIMIxVIknWL7SWAK_P3_e-kbYWq6hfJGTDp7RB5GMElng_Qfkzt-84TcX8Tl8qdkP8dXMcCFwavR-Vd5QpcUJ-vpdtgc6zvat7Tfrdst01FU3lH430jT2dGPy9ms-wTXjl62a_SU7a6j66uBv6nXzIEK_5n0WLTQ4xm5OPu2nJ-zWGyB2TKXPbOZhtwJ4JovXdoYLyqt8Rx4pmvuuWmq0mtRm9w7tPucm0rYtKlrLzMPfYriOTnatBv_klBRNBbTJpdbzcNSZl1ozBNdYa0TdUKyw59WNjKRY0GMXypkJFKoQToKXqOCdNQ-ISdjn-uBh-PWp7-gAMcnkUM73Gi3P1U0SQVY0pq08dYbyTOdaqOlqziM0MEH6Twh71D8ajiQOnoCNaukqHlVV2lCjg-aoaLpd-qfoibk_dgMRovC1RsPUlKhYBiC7SwhLwZFGsdaSMBwZQUtcqJik4-ZtmyuLgMxeIbkgRnPXt0-rtfkQT4oPvjIY3LUb3f-DUCr3rwN9vMXEU4gTA priority: 102 providerName: ProQuest |
Title | Cross-reactive CD8+ T cell responses to tumor-associated antigens (TAAs) and homologous microbiota-derived antigens (MoAs) |
URI | https://www.ncbi.nlm.nih.gov/pubmed/38509571 https://www.proquest.com/docview/3037874169 https://www.proquest.com/docview/2973101611 https://pubmed.ncbi.nlm.nih.gov/PMC10953141 https://doaj.org/article/232cb0feceb841a0aba8d74cd6d8e5a2 |
Volume | 43 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1bb9MwFLZ2kaa9IO4ERjESD6ApECeO7Twg1JZNE1InNLXSxItlOw6btDbQpAjGn-fYuWgRg5dKbXKa2Of2nTj-DkKvtOuApAsTMqFNSFUMcVCzFEoVa4XQCiCJKxRnp-xkQT-dp-dbqGt31E5gdWtp5_pJLdZXb39-__UBHP69d3jB3lXELe-FkG3CyBFIhdfbaBcyE3eOOqP9qgLUCiTrNs7cKreP9hIBKTTlZJCnPJ3_30H7RtYavlF5I0Ud30V3WmyJx40x3ENbdnUf7c3a1fMH6PfUXSoEmOiDHJ5-FPgQz7F7eI_XzcuytsJ1ievNslyHqlWdzTHMv6PtrPDr-XhcvYHvOb4oly5ylpsKLy8bPqdahTmY9I-BxKwEiYdocXw0n56EbfOF0KSxqENDFNRSAN9smkeFtowr5faFE5VRS3XBU6tYpmObuzgQU82ZiYoss4JYkEmSR2hnVa7sE4RZUhhXRuWxUdQvbWaJcnVjnhiTsyxApJtqaVpmctcg40r6CkUw2WhKwmWk15S8DtBhL_Ot4eX479kTp8H-TMep7X8o119l66ISsKXRUWGN1YISFSmtRM4p3GEOA1JxgF44_ctmg2ofGeSYC5ZRnvEoQAedacjOkiVgBAiKgHthnC_7w-DETrlqZUFL0jcQc-CbBOhxY0n9vXYGGSAxsLHBYIZHVpcXniicODJBQsnTf_7pM7QfN_YP4fIA7dTrjX0OKKvWI7TNz_kI7U6OTj-fjfyzipF3J_g8m3z5A33uJjc |
linkProvider | Scholars Portal |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9NAEF5VqQRcEG8MhS4SSKBqVdux1-sDQmnaKqVNhFAq9bbdl2klEpfYAZEfxW9kxo9QC6m3HpP1xuvMzDfzeXZnCHmrsQOSzgzjQhsWqRBwUPMYqIpzQmgFIQkSxfGEj06jz2fx2Qb5056FwW2VLSZWQG1zg-_IdwFqQbcgfEg_Xf1g2DUKs6ttC41aLY7d719A2YqPR_sg33dheHgwHY5Y01WAmTgUJTOBApIAcYmLrZ9pxxOl8MBzoNLIRTpLYqd4qkNnUcHDSCfc-FmaOhE4mIMvQAHyN6M-UJke2dw7mHz52mI_sJGqlQj4ZM6QSbTHdATfLQJMQjL4ReZjmSu26rjCqmPA_37hmmPsbtq85gUPH5D7TfhKB7W-PSQbbv6I3Bk3CfrHZDXEWzGIRCscpcN9sUOnFNMDdFFvx3UFLXNaLmf5gqlGOZylIGEsDFrQ99PBoPgAny29yGeIzfmyoLPLumJUqZgFo_nZmTHOYcYTcnorgnhKevN87p4TyvuZQaJmQ6OiKnma9hUyU9s3xvLUI0H7T0vT1D7HFhzfZcWBBJe1dCTcRlbSkSuP7KznXNWVP268eg8FuL4Sq3ZXX-SLb7IBAQnRq9F-5ozTIgqUr7QSNolghRYeSIUe2Ubxy_oI7Bp75CARPI2SNPE9stVqhmzAppD_TMMjb9bDABMoXDV3ICVZtSjD8D7wyLNakdZr7QuIGuMERkRHxToP0x2ZX15UpcgDLFcYRMGLm9e1Te6OpuMTeXI0OX5J7oW1EQBCb5FeuVi6VxDYlfp1Y02UnN-2Af8Fe0deWw |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Cross-reactive+CD8+%2B+T+cell+responses+to+tumor-associated+antigens+%28TAAs%29+and+homologous+microbiota-derived+antigens+%28MoAs%29&rft.jtitle=Journal+of+experimental+%26+clinical+cancer+research&rft.au=Cavalluzzo%2C+Beatrice&rft.au=Viuff%2C+Marie+Christine&rft.au=Tvingsholm%2C+Siri+Amanda&rft.au=Ragone%2C+Concetta&rft.date=2024-03-20&rft.eissn=1756-9966&rft.volume=43&rft.issue=1&rft.spage=87&rft_id=info:doi/10.1186%2Fs13046-024-03004-z&rft_id=info%3Apmid%2F38509571&rft.externalDocID=38509571 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1756-9966&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1756-9966&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1756-9966&client=summon |